Related references
Note: Only part of the references are listed.Dissecting the roles of β-arrestin2 and GSK-3 signaling in 5-HT1BR-mediated perseverative behavior and prepulse inhibition deficits in mice
Summer L. Thompson et al.
PLOS ONE (2019)
Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease
Nidhi Sharma et al.
NEUROBIOLOGY OF DISEASE (2019)
Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions
A. Prasanth Saraswati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity
Chao Wu et al.
NEUROBIOLOGY OF AGING (2018)
Sensory and Behavioral Responses of a Model Fish to Oil Sands Process-Affected Water with and without Treatment
Megan Reichert et al.
ENVIRONMENTAL SCIENCE & TECHNOLOGY (2017)
The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis
Paloma Perez-Domper et al.
NEUROPHARMACOLOGY (2017)
Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series
Davangere P. Devanand et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2017)
Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease
Mudasir Maqbool et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis
Qing-Fei Zhao et al.
JOURNAL OF AFFECTIVE DISORDERS (2016)
Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors
Guanglin Luo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease
Kenji Fukunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Fluoxetine Regulates Neurogenesis In Vitro Through Modulation of GSK-3β/β-Catenin Signaling
Jiaojie Hui et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
A Phase II Trial of Tideglusib in Alzheimer's Disease
Simon Lovestone et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Auditory post-processing in a passive listening task is deficient in Alzheimer's disease
Stephan Bender et al.
CLINICAL NEUROPHYSIOLOGY (2014)
Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects?
Catherine Belzung
NEUROPSYCHOPHARMACOLOGY (2014)
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments
Margaret K. King et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Predictors of progression to severe Alzheimer's disease in an incidence sample
Peter V. Rabins et al.
ALZHEIMERS & DEMENTIA (2013)
2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors
Kenji Fukunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors
Fumiaki Uehara et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as New Glycogen Synthase Kinase-3β Inhibitors
Valeria La Pietra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties
P. A. Zunszain et al.
MOLECULAR PSYCHIATRY (2013)
GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of Ketamine
Rong-Jian Liu et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease
Hongxing Wang et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse
Nicole M. Enman et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents
Guy Griebel et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Time-Course and Regional Analyses of the Physiopathological Changes Induced after Cerebral Injection of an Amyloid β Fragment in Rats
Charleine Zussy et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Glycogen synthase kinase 3β in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization
Chun-mei Xu et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Cognitive dysfunctions induced by a cholinergic blockade and Aβ25-35 peptide are attenuated by salvianolic acid B
Dong Hyun Kim et al.
NEUROPHARMACOLOGY (2011)
BEHAVIORAL PHENOTYPING OF V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1-DEFICIENT MICE REVEALS A SEX-SPECIFIC PREPULSE INHIBITION DEFICIT IN FEMALES THAT CAN BE PARTIALLY ALLEVIATED BY GLYCOGEN SYNTHASE KINASE-3 INHIBITORS BUT NOT BY ANTIPSYCHOTICS
Y. W. Chen et al.
NEUROSCIENCE (2011)
Genetic and Pharmacological Evidence for Schizophrenia-Related Disc1 Interaction With GSK-3
Tatiana V. Lipina et al.
SYNAPSE (2011)
Protein Phosphatase 2A and Glycogen Synthase Kinase 3 Signaling Modulate Prepulse Inhibition of the Acoustic Startle Response by Altering Cortical M-Type Potassium Channel Activity
David Kapfhamer et al.
JOURNAL OF NEUROSCIENCE (2010)
A kinesin signaling complex mediates the ability of GSK-3β to affect mood-associated behaviors
Jing Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Glycogen synthase kinase 3 beta in the nucleus accumbens core mediates cocaine-induced behavioral sensitization
Chun-mei Xu et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Kurt R. Brunden et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Cocaine-induced hyperactivity and sensitization are dependent on GSK3
Jonathan S. Miller et al.
NEUROPHARMACOLOGY (2009)
Dopaminergic Response to Graded Dopamine Concentration Elicited by Four Amphetamine Doses
Jiaqian Ren et al.
SYNAPSE (2009)
Phosphorylated tau in neuritic plaques of APPsw/Tauvlw transgenic mice and Alzheimer disease
Mar Perez et al.
ACTA NEUROPATHOLOGICA (2008)
Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey
Ipek Yalcin et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs
Ana Martinez
MEDICINAL RESEARCH REVIEWS (2008)
Role of GSK3β in behavioral abnormalities induced by serotonin deficiency
Jean-Martin Beaulieu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice
Angelo O. Rosa et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
The GSK3 hypothesis of Alzheimer's disease
Claudie Hooper et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Chronic lithium treatment magnifies learning in rats
C. Nocjar et al.
NEUROSCIENCE (2007)
The role of glycogen synthase kinase-3β in schizophrenia
Eliza Koros et al.
DRUG NEWS & PERSPECTIVES (2007)
Enhancing effects of lithium on memory are not by-products of learning or attentional deficits
Eleftheria Tsaltas et al.
BEHAVIOURAL BRAIN RESEARCH (2007)
Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE (2007)
Enhancing effects of chronic lithium on memory in the rat
Eleftheria Tsaltas et al.
BEHAVIOURAL BRAIN RESEARCH (2007)
Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics
Xiaohua Li et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2007)
Antidepressant-like effects of the corticotropin-releasing factor I receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72s schedule in the rat
Caroline Louis et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease
Iacopo Cancelli et al.
JOURNAL OF CLINICAL NEUROPHYSIOLOGY (2006)
Transgenic mice overexpressing glycogen synthase kinase 3β:: A putative model of hyperactivity and mania
Jos Prickaerts et al.
JOURNAL OF NEUROSCIENCE (2006)
Psychotropic drugs affect Ser9-phosphorylated GSK-3β protein levels in rodent frontal cortex
Nitsan Kozlovsky et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3
Tobias Engel et al.
JOURNAL OF NEUROSCIENCE (2006)
The effects of antipsychotics on β-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats
H Alimohamad et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum
H Alimohamad et al.
BIOLOGICAL PSYCHIATRY (2005)
Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule
JM O'Donnell et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2005)
Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus
O Kaidanovich-Beilin et al.
BIOLOGICAL PSYCHIATRY (2004)
Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia
ES Emamian et al.
NATURE GENETICS (2004)
Prepulse inhibition in patients with Alzheimer's disease
AM Hejl et al.
NEUROBIOLOGY OF AGING (2004)
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test
TD Gould et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Transgenic animal models of Alzheimer's disease and related disorders:: Histopathology, behavior and therapy
J Götz et al.
MOLECULAR PSYCHIATRY (2004)
Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing
Y Su et al.
BIOCHEMISTRY (2004)
Diverse psychotomimetics act through a common signaling pathway
P Svenningsson et al.
SCIENCE (2003)
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
CJ Phiel et al.
NATURE (2003)
The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
DC Blanchard et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release
A Balla et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
G Griebel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease
F Jessen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation
S Frame et al.
MOLECULAR CELL (2001)
Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice
JJ Lucas et al.
EMBO JOURNAL (2001)
Memory deficits and increased emotionality induced by beta-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus
A Olariu et al.
JOURNAL OF NEURAL TRANSMISSION (2001)
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
K Yamada et al.
PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
